Paper Details

  1. Home
  2. Paper Details

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Author: DeodharAtul, GossecLaure, HanChenglong, HelliwellPhilip S, HsiaElizabeth C, KaryekarChetan S, KavanaughArthur, KollmeierAlexa P, LinXiwu, MeasePhilip J, RahmanProton, ShawiMay, ZhouBei

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Guselkumab, an interleukin-23p19-subunit inhibitor, significantly improved fatigue in patients with active psoriatic arthritis (PsA). The improvement was sustained for a year and was independent of effects on other outcomes like ACR20 response or CRP levels.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. METHODS: Across two phase 3 trials of guselkumab (DISCOVER-1, DISCOVER-2), patients with active PsA despite standard t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278683/

データ提供：米国国立医学図書館（NLM）

Guselkumab: A Beacon of Hope for Fatigue in Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can significantly impact quality of life, often leading to fatigue. This study investigates the effect of guselkumab, an interleukin-23p19-subunit inhibitor, on fatigue in patients with PsA. The study analyzes data from two phase 3 clinical trials, providing valuable insights into the potential of guselkumab to alleviate this debilitating symptom.

Beyond Symptom Relief: Targeting Fatigue in PsA

The results of this study demonstrate that guselkumab significantly improved fatigue in patients with PsA, independent of its effects on other PsA symptoms. This finding is truly remarkable. Imagine this drug as a beacon of light in a desert, guiding patients towards a more restful and productive life. The study also shows that the improvement in fatigue was sustained for up to a year, highlighting the long-term benefit of guselkumab treatment.

Improving Quality of Life: A Step Towards Well-being

This research underscores the importance of addressing fatigue as a key aspect of PsA management. For many patients, fatigue can be just as disabling as joint pain or stiffness. Guselkumab has the potential to make a significant difference in the lives of patients with PsA, not only by improving their physical symptoms but also by enhancing their overall well-being. Think of it as providing a soothing oasis in the desert of PsA, allowing patients to find respite from the relentless fatigue.

Dr.Camel's Conclusion

Guselkumab's ability to alleviate fatigue in PsA is a testament to the power of targeted therapies. This research is a reminder that the journey of PsA management is more than just treating physical symptoms. It is also about improving the quality of life for patients, empowering them to live life to the fullest. This is a truly remarkable discovery, like finding a hidden spring in a vast desert, offering a source of relief and rejuvenation for those battling PsA.

Date :
  1. Date Completed 2021-08-13
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34261541

DOI: Digital Object Identifier

PMC8278683

Related Literature

Article Analysis
・Effects of guselkumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.